BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9815740)

  • 1. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
    Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
    Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
    Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
    Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia.
    Powell BL; Lyerly ES; Motsinger CP; Cruz JM; Chorley HM; Hurd DD; Cooper MR
    Leukemia; 1995 May; 9(5):770-3. PubMed ID: 7769838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.
    Lowe ES; Kitchen BJ; Erdmann G; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Woods W; Franklin J; Widemann BC; Balis FM; Murphy RF; Adamson PC
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):199-205. PubMed ID: 11320662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
    Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
    Cairo MS; Siegel S; Anas N; Sender L
    Cancer Res; 1989 Feb; 49(4):1063-6. PubMed ID: 2536292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM; Blakley RL; Santana VM; Crom WR
    Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vivo and in vitro effects of continuous exposure of L1210 cells to 6-thioguanine.
    Maybaum J; Morgans CW; Hink LA
    Cancer Res; 1987 Jun; 47(12):3083-7. PubMed ID: 3581060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.